<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Leung AKL</submitter><funding>NIAID NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIGMS NIH HHS</funding><funding>NIH HHS</funding><pagination>94</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8780475</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>Emerging and re-emerging viral diseases pose continuous public health threats, and effective control requires a combination of non-pharmacologic interventions, treatment with antivirals, and prevention with vaccines. The COVID-19 pandemic has demonstrated that the world was least prepared to provide effective treatments. This lack of preparedness has been due, in large part, to a lack of investment in developing a diverse portfolio of antiviral agents, particularly those ready to combat viruses of pandemic potential. Here, we focus on a drug target called macrodomain that is critical for the replication and pathogenesis of alphaviruses and coronaviruses. Some mutations in alphavirus and coronaviral macrodomains are not tolerated for virus replication. In addition, the coronavirus macrodoma</pubmed_abstract><journal>Pathogens (Basel, Switzerland)</journal><pubmed_title>The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses.</pubmed_title><pmcid>PMC8780475</pmcid><funding_grant_id>R35 GM138029</funding_grant_id><funding_grant_id>R01 GM104135</funding_grant_id><funding_grant_id>R56 AI137264</funding_grant_id><funding_grant_id>K22AI134933</funding_grant_id><funding_grant_id>R56AI137264</funding_grant_id><funding_grant_id>R01GM104135</funding_grant_id><funding_grant_id>R35GM138029</funding_grant_id><pubmed_authors>Fehr AR</pubmed_authors><pubmed_authors>Leung AKL</pubmed_authors><pubmed_authors>Griffin DE</pubmed_authors><pubmed_authors>Bosch J</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses.</name><description>Emerging and re-emerging viral diseases pose continuous public health threats, and effective control requires a combination of non-pharmacologic interventions, treatment with antivirals, and prevention with vaccines. The COVID-19 pandemic has demonstrated that the world was least prepared to provide effective treatments. This lack of preparedness has been due, in large part, to a lack of investment in developing a diverse portfolio of antiviral agents, particularly those ready to combat viruses of pandemic potential. Here, we focus on a drug target called macrodomain that is critical for the replication and pathogenesis of alphaviruses and coronaviruses. Some mutations in alphavirus and coronaviral macrodomains are not tolerated for virus replication. In addition, the coronavirus macrodoma</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-21T17:36:55.39Z</modification><creation>2022-02-11T15:51:06.944Z</creation></dates><accession>S-EPMC8780475</accession><cross_references><pubmed>35056042</pubmed><doi>10.3390/pathogens11010094</doi></cross_references></HashMap>